ClinicalTrials.gg

Program

Bivalent RSV+HMPV protein vaccine

A development code.

Its studies are led by Sanofi.

Furthest: phase 2, since Sep 3, 20261 company-led study, 1 open or runningNext primary completion: Jul 3, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 2since Sep 3, 2026Sep 3, 2026Jul 3, 2028phase 2 · NCT07810010

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2026First study: phase 2 study in Respiratory Syncytial VirusFirst studyNCT07810010 · 8,000 planned · Australia, United Kingdom

Ahead

  1. Jul 3, 2028Primary completion: phase 2 study in Respiratory Syncytial VirusNCT07810010

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bivalent RSV+HMPV protein vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07810010Respiratory Syncytial Virus · Australia, United Kingdom2RecruitingJul 3, 20288,000

How it is read

Names in the registry

  • “Bivalent RSV+HMPV protein vaccine”, 1 entry

Codes read as this program: RPF08203.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.